Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

GUSTAVO ALVA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1417030222
CMS profile
154803
Location
ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$698,264.08

902 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 12 of 19; records 551–600 of 902 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

GUSTAVO ALVA

NPI 1417030222 · CMS profile ID 154803

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

ORANGE, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 12 of 19; records 551–600 of 902 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1417030222?year=2019&recipient=provider&page=12#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
GUSTAVO ALVA, NPI 1417030222, CMS profile ID 154803. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 19; records 551–600 of 902 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1417030222?year=2019&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). GUSTAVO ALVA, NPI 1417030222, CMS profile ID 154803. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 12 of 19; records 551–600 of 902 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1417030222?year=2019&recipient=provider&page=12#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
GUSTAVO ALVA, NPI 1417030222, CMS profile ID 154803, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 12 of 19; records 551–600 of 902 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1417030222?year=2019&recipient=provider&page=12#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

902 matching records · $698,264.08 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 902 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 551–600 of 902.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Teva Pharmaceuticals USA, Inc. $862.1406/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697857021 CMS
Janssen Pharmaceuticals, Inc $119.2406/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658265189 CMS
Teva Pharmaceuticals USA, Inc. $605.2006/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697856997 CMS
Avanir Pharmaceuticals, Inc. $2,340.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653586771 CMS
Avanir Pharmaceuticals, Inc. $3,400.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653587017 CMS
H. Lundbeck A S $824.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681161149 CMS
H. Lundbeck A S $279.7806/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681161151 CMS
H. Lundbeck A S $108.0506/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681161159 CMS
H. Lundbeck A S $2,400.0006/03/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681161163 CMS
H. Lundbeck A S $865.4506/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681161169 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697856971 CMS
Teva Pharmaceuticals USA, Inc. $3,030.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697856993 CMS
Teva Pharmaceuticals USA, Inc. $3,030.0006/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697857055 CMS
Alkermes, Inc. $2,500.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686570711 CMS
Neurocrine Biosciences, Inc. $2,000.0005/31/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693111373 CMS
Neurocrine Biosciences, Inc. $28.4005/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693111375 CMS
Sunovion Pharmaceuticals Inc. $21.5305/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688097863 CMS
Sunovion Pharmaceuticals Inc. $3,017.5005/29/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688097825 CMS
Sunovion Pharmaceuticals Inc. $123.9405/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688097827 CMS
Teva Pharmaceuticals USA, Inc. $16.1505/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697712499 CMS
Allergan Inc. $11.4705/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670025897 CMS
Avanir Pharmaceuticals, Inc. $126.5005/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653586769 CMS
Avanir Pharmaceuticals, Inc. $19.0905/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653587011 CMS
Avanir Pharmaceuticals, Inc. $1,362.3605/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 653587015 CMS
Allergan Inc. $19.6005/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670025895 CMS
Otsuka America Pharmaceutical, Inc. $3.3805/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687342181 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0005/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697856961 CMS
Janssen Pharmaceuticals, Inc $24.7705/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658265187 CMS
Teva Pharmaceuticals USA, Inc. $17.4405/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697755635 CMS
Teva Pharmaceuticals USA, Inc. $3,030.0005/23/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697857075 CMS
ACADIA Pharmaceuticals Inc $464.6005/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991583 CMS
ACADIA Pharmaceuticals Inc $125.0005/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991585 CMS
ACADIA Pharmaceuticals Inc $452.9705/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991587 CMS
ACADIA Pharmaceuticals Inc $6,400.0005/22/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991589 CMS
ACADIA Pharmaceuticals Inc $22.9605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991591 CMS
ACADIA Pharmaceuticals Inc $22.9605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991593 CMS
ACADIA Pharmaceuticals Inc $50.0705/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991595 CMS
ACADIA Pharmaceuticals Inc $74.2605/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991597 CMS
ACADIA Pharmaceuticals Inc $48.0005/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991599 CMS
ACADIA Pharmaceuticals Inc $48.0005/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991601 CMS
ACADIA Pharmaceuticals Inc $125.0005/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699991603 CMS
Alkermes, Inc. $15.0305/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686570777 CMS
Allergan Inc. $4.7005/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670025891 CMS
Sunovion Pharmaceuticals Inc. $24.8505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688097861 CMS
Teva Pharmaceuticals USA, Inc. $3.1505/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697804805 CMS
Alkermes, Inc. $5,400.0005/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686570719 CMS
Otsuka America Pharmaceutical, Inc. $4.4805/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687342179 CMS
Allergan Inc. $19.2405/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670025853 CMS
Allergan Inc. $3,750.0005/19/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670025859 CMS
Allergan Inc. $100.1605/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670025862 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $698,264.08 902
PY2020 $443,106.19 673
PY2021 $594,153.49 870
PY2022 $777,103.29 1,057
PY2023 $1,066,079.45 1,079
PY2024 $1,052,847.81 1,075
PY2025 $1,138,181.83 1,015

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $574,768.04 446
PY2024 Principal investigator $656,148.43 215
PY2023 Recipient $410.00 1
PY2023 Principal investigator $666,531.50 126
PY2022 Recipient $300.00 1
PY2022 Principal investigator $616,740.43 91
PY2021 Recipient $45,232.44 10
PY2021 Principal investigator $312,012.37 72
PY2020 Recipient $4,998.75 1
PY2020 Principal investigator $566,081.60 159
PY2019 Principal investigator $623,807.72 119

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

446 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $849.84 12/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A 52-Week, Multicenter, Open-Label, Flexible-dose Study to Evaluate the Long-term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Subjects with Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder No dispute reported 06/30/2026 1202533803
Principal investigator 1 ABBVIE INC. $1,099.68 12/31/2025 Non-covered Recipient Entity
CLINNOVA RESEARCH SOLUTIONS
A 6-week, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study of the Efficacy and Safety of Cariprazine in Pediatric Subjects (10 to 17 years of age) in the Treatment of Depressive Episodes Associated with Bipolar I Disorder No dispute reported 06/30/2026 1202533805
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 12/17/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042961
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 12/17/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042983
Principal investigator 1 Eli Lilly and Company $52.46 12/11/2025 Non-covered Recipient Entity
ATP CLINICAL RESEARCH
A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ADJUNCTIVE TREATMENT WITH BRENIPATIDE IN DELAYING TIME TO RELAPSE COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH MAJOR DEPRESSIVE DISORDER (RENEW-MDD 1) No dispute reported 06/30/2026 1187877127
Principal investigator 1 Janssen Research & Development, LLC $3,975.00 12/08/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175424820
Principal investigator 1 ABBVIE INC. $12,500.00 12/04/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder No dispute reported 06/30/2026 1202527582
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624112
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624114
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624116
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624118
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624120
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624122
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624124
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624126
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624128
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624130
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624132
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624134
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624136
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624138
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624140
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624142
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624144
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624146
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624148
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624150
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624152
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624154
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624156
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624158
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624160
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624162
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624164
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624166
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624168
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624170
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624172
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624174
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624176
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624178
Principal investigator 1 Boehringer Ingelheim International GmbH $350.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624180
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624182
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624184
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624186
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624188
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624190
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624192
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624194
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624196
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624198
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624200
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624202
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624204
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624206
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624208
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624210
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624212
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624214
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 11/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624216
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 11/19/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042957
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $822.00 11/19/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042959
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 11/19/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042981
Principal investigator 1 LivaNova USA, Inc. $72.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559004
Principal investigator 1 LivaNova USA, Inc. $282.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559009
Principal investigator 1 LivaNova USA, Inc. $969.60 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559013
Principal investigator 1 LivaNova USA, Inc. $969.60 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559017
Principal investigator 1 LivaNova USA, Inc. $969.60 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559020
Principal investigator 1 LivaNova USA, Inc. $969.60 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559025
Principal investigator 1 LivaNova USA, Inc. $72.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559029
Principal investigator 1 LivaNova USA, Inc. $72.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559032
Principal investigator 1 LivaNova USA, Inc. $72.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559037
Principal investigator 1 LivaNova USA, Inc. $72.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559041
Principal investigator 1 LivaNova USA, Inc. $282.00 11/11/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559045
Principal investigator 1 LivaNova USA, Inc. $1,729.20 10/24/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556334
Principal investigator 1 Janssen Research & Development, LLC $33,000.00 10/20/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorder (MDD) No dispute reported 06/30/2026 1175424848
Principal investigator 1 LivaNova USA, Inc. $282.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245558997
Principal investigator 1 LivaNova USA, Inc. $282.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559001
Principal investigator 1 LivaNova USA, Inc. $282.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559184
Principal investigator 1 LivaNova USA, Inc. $6.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559189
Principal investigator 1 LivaNova USA, Inc. $2,031.60 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559193
Principal investigator 1 LivaNova USA, Inc. $72.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559197
Principal investigator 1 LivaNova USA, Inc. $969.60 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559201
Principal investigator 1 LivaNova USA, Inc. $918.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559204
Principal investigator 1 LivaNova USA, Inc. $969.60 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559388
Principal investigator 1 LivaNova USA, Inc. $969.60 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559391
Principal investigator 1 LivaNova USA, Inc. $969.60 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559395
Principal investigator 1 LivaNova USA, Inc. $72.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559399
Principal investigator 1 LivaNova USA, Inc. $72.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559403
Principal investigator 1 LivaNova USA, Inc. $72.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559409
Principal investigator 1 LivaNova USA, Inc. $72.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559414
Principal investigator 1 LivaNova USA, Inc. $282.00 10/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559416
Principal investigator 1 ABBVIE INC. $60.00 10/07/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202513483
Principal investigator 1 Janssen Research & Development, LLC $975.00 10/06/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175170753
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624052
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624054
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624056
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624058
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624060
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624062
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624064
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624066
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624068
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624070
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624072
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624074
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624076
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624078
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624080
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624082
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624084
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624086
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624088
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624090
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624092
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624094
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624096
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624098
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624100
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624102
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624104
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624106
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624108
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 10/02/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624110
Principal investigator 1 Indivior Inc. $190.25 10/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468817
Principal investigator 1 Indivior Inc. $329.50 10/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468819
Principal investigator 1 Indivior Inc. $329.50 10/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468821
Principal investigator 1 Indivior Inc. $190.25 10/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468823
Principal investigator 1 Indivior Inc. $329.50 10/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240468825
Principal investigator 1 ABBVIE INC. $520.47 09/24/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202512160
Principal investigator 1 ABBVIE INC. $182.00 09/22/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202511836
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 09/15/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042955
Principal investigator 1 ACADIA Pharmaceuticals Inc $12,161.00 09/10/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ACP-204-012 No dispute reported 06/30/2026 1245936085
Principal investigator 1 LivaNova USA, Inc. $282.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559208
Principal investigator 1 LivaNova USA, Inc. $72.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559211
Principal investigator 1 LivaNova USA, Inc. $993.60 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559215
Principal investigator 1 LivaNova USA, Inc. $969.60 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559218
Principal investigator 1 LivaNova USA, Inc. $918.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559222
Principal investigator 1 LivaNova USA, Inc. $918.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559360
Principal investigator 1 LivaNova USA, Inc. $969.60 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559365
Principal investigator 1 LivaNova USA, Inc. $72.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559369
Principal investigator 1 LivaNova USA, Inc. $72.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559372
Principal investigator 1 LivaNova USA, Inc. $72.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559376
Principal investigator 1 LivaNova USA, Inc. $282.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559380
Principal investigator 1 LivaNova USA, Inc. $282.00 09/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559384
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $130.00 09/02/2025 Non-covered Recipient Entity
Pacific Neuropsychiatric Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease No dispute reported 06/30/2026 1235994808
Principal investigator 1 Eli Lilly and Company $19.00 08/26/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187883404
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,968.00 08/25/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ACP-204-006 No dispute reported 06/30/2026 1245935679
Principal investigator 1 Janssen Research & Development, LLC $8,515.00 08/25/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424813
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624016
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624018
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624020
Principal investigator 1 Boehringer Ingelheim International GmbH $1,225.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624022
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624024
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624026
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624028
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624030
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624032
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624034
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624036
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624038
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624040
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624042
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624044
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624046
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624048
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 08/22/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624050
Principal investigator 1 Indivior Inc. $190.25 08/20/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467939
Principal investigator 1 Indivior Inc. $190.25 08/20/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467941
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559225
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559230
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559234
Principal investigator 1 LivaNova USA, Inc. $918.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559238
Principal investigator 1 LivaNova USA, Inc. $918.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559242
Principal investigator 1 LivaNova USA, Inc. $918.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559247
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559251
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559255
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559258
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559262
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559267
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559272
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559275
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559281
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559285
Principal investigator 1 LivaNova USA, Inc. $72.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559290
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559293
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559296
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559299
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559301
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559304
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559307
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559310
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559314
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559318
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559322
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559325
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559330
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559334
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559337
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559340
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559345
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559349
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559353
Principal investigator 1 LivaNova USA, Inc. $282.00 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559356
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559423
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559427
Principal investigator 1 LivaNova USA, Inc. $969.60 08/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559431
Principal investigator 1 LivaNova USA, Inc. $1,345.00 08/07/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556292
Principal investigator 1 Janssen Research & Development, LLC $1,150.00 08/04/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175170436
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $50,751.29 08/01/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220812526
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623996
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623998
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624000
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624002
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624004
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624006
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624008
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624010
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624012
Principal investigator 1 Boehringer Ingelheim International GmbH $538.00 07/28/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624014
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,500.00 07/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-201 No dispute reported 06/30/2026 1242355492
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,032.00 07/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-201 No dispute reported 06/30/2026 1242355494
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 07/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-201 No dispute reported 06/30/2026 1242355496
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,500.00 07/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242355506
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $2,032.00 07/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242355508
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $650.00 07/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242355510
Principal investigator 1 ABBVIE INC. $4,215.00 07/24/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC DBA ATP CLINICAL RESEARCH
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202499682
Principal investigator 1 Indivior Inc. $190.25 07/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467453
Principal investigator 1 Indivior Inc. $190.25 07/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467541
Principal investigator 1 Indivior Inc. $190.25 07/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467563
Principal investigator 1 Indivior Inc. $190.25 07/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467575
Principal investigator 1 Indivior Inc. $971.00 07/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467597
Principal investigator 1 Indivior Inc. $190.25 06/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467199
Principal investigator 1 Indivior Inc. $329.50 06/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467201
Principal investigator 1 Indivior Inc. $329.50 06/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467203
Principal investigator 1 Indivior Inc. $190.25 06/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467205
Principal investigator 1 Indivior Inc. $329.50 06/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467207
Principal investigator 1 Indivior Inc. $190.25 06/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240467209
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623922
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623924
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623926
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623928
Principal investigator 1 Boehringer Ingelheim International GmbH $300.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623930
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623932
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623934
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623936
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623938
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623940
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623942
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623944
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623946
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623948
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623950
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623952
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623954
Principal investigator 1 Boehringer Ingelheim International GmbH $1,150.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623956
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623958
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623960
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623962
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623964
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623966
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623968
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623970
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623972
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623974
Principal investigator 1 Boehringer Ingelheim International GmbH $900.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623976
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623978
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623980
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623982
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623984
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623986
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623988
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623990
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623992
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 06/25/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623994
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $109.00 06/25/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
A phase III trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-2) No dispute reported 06/30/2026 1220812518
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $269.74 06/23/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220812524
Principal investigator 1 LivaNova USA, Inc. $90.00 06/17/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556833
Principal investigator 1 Janssen Research & Development, LLC $975.00 06/13/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175170685
Principal investigator 1 LivaNova USA, Inc. $282.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559061
Principal investigator 1 LivaNova USA, Inc. $72.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559065
Principal investigator 1 LivaNova USA, Inc. $918.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559072
Principal investigator 1 LivaNova USA, Inc. $969.60 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559076
Principal investigator 1 LivaNova USA, Inc. $282.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559079
Principal investigator 1 LivaNova USA, Inc. $282.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559084
Principal investigator 1 LivaNova USA, Inc. $282.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559088
Principal investigator 1 LivaNova USA, Inc. $72.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559092
Principal investigator 1 LivaNova USA, Inc. $72.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559096
Principal investigator 1 LivaNova USA, Inc. $918.00 06/10/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559100
Principal investigator 1 Janssen Research & Development, LLC $18,600.00 05/30/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia VENTURA-5 No dispute reported 06/30/2026 1175424860
Principal investigator 1 Boehringer Ingelheim International GmbH $2,006.00 05/27/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623916
Principal investigator 1 Boehringer Ingelheim International GmbH $100.00 05/27/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623918
Principal investigator 1 Janssen Research & Development, LLC $3,421.00 05/26/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424842
Principal investigator 1 Boehringer Ingelheim International GmbH $650.00 05/14/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623912
Principal investigator 1 Boehringer Ingelheim International GmbH $8,000.00 05/14/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623914
Principal investigator 1 Boehringer Ingelheim International GmbH $1,750.00 05/14/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220623920
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042951
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042953
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042963
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042965
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042967
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042969
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042971
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042973
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042975
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042977
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042979
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 05/14/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042985
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559049
Principal investigator 1 LivaNova USA, Inc. $918.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559053
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559057
Principal investigator 1 LivaNova USA, Inc. $282.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559068
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559104
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559108
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559112
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559116
Principal investigator 1 LivaNova USA, Inc. $918.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559121
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559124
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559128
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559132
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559135
Principal investigator 1 LivaNova USA, Inc. $969.60 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559140
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559144
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559147
Principal investigator 1 LivaNova USA, Inc. $72.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559151
Principal investigator 1 LivaNova USA, Inc. $282.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559154
Principal investigator 1 LivaNova USA, Inc. $282.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559158
Principal investigator 1 LivaNova USA, Inc. $282.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559161
Principal investigator 1 LivaNova USA, Inc. $282.00 05/09/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559163
Principal investigator 1 Janssen Research & Development, LLC $1,950.00 05/07/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175170581
Principal investigator 1 Janssen Research & Development, LLC $7,818.00 04/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424866
Principal investigator 1 Janssen Research & Development, LLC $3,421.00 04/25/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424852
Principal investigator 1 Indivior Inc. $190.25 04/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465917
Principal investigator 1 Indivior Inc. $190.25 04/23/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465919
Principal investigator 1 ABBVIE INC. $8,875.00 04/18/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC DBA ATP CLINICAL RESEARCH
A Study to Evaluate Efficacy, Safety, and Tolerability of Darigabat in Participants With Panic Disorder No dispute reported 06/30/2026 1202478126
Principal investigator 1 Janssen Research & Development, LLC $1,325.00 04/09/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175170565
Principal investigator 1 LivaNova USA, Inc. $282.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559166
Principal investigator 1 LivaNova USA, Inc. $282.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559169
Principal investigator 1 LivaNova USA, Inc. $282.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559174
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559178
Principal investigator 1 LivaNova USA, Inc. $918.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559182
Principal investigator 1 LivaNova USA, Inc. $918.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559674
Principal investigator 1 LivaNova USA, Inc. $969.60 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559679
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559683
Principal investigator 1 LivaNova USA, Inc. $282.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559686
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559691
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559695
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559699
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559702
Principal investigator 1 LivaNova USA, Inc. $72.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559707
Principal investigator 1 LivaNova USA, Inc. $918.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559711
Principal investigator 1 LivaNova USA, Inc. $969.60 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559715
Principal investigator 1 LivaNova USA, Inc. $969.60 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559719
Principal investigator 1 LivaNova USA, Inc. $969.60 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559724
Principal investigator 1 LivaNova USA, Inc. $969.60 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559733
Principal investigator 1 LivaNova USA, Inc. $918.00 04/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559737
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $213.30 04/04/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220812520
Principal investigator 1 ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) $8,000.00 04/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
ITI-1284-101 No dispute reported 06/30/2026 1242338927
Principal investigator 1 Indivior Inc. $190.25 04/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465423
Principal investigator 1 Indivior Inc. $329.50 04/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465425
Principal investigator 1 Indivior Inc. $971.00 04/02/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240465427
Principal investigator 1 Janssen Research & Development, LLC $4,155.00 03/31/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424825
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $300.82 03/24/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X) No dispute reported 06/30/2026 1220812522
Principal investigator 1 ABBVIE INC. $2,356.20 03/19/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202464887
Principal investigator 1 Janssen Research & Development, LLC $4,350.00 03/12/2025 Non-covered Recipient Entity
Clinnova Rsrch Solutions Corp.
A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE) No dispute reported 06/30/2026 1175170638
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $46,298.97 03/10/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
A phase III trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-2) No dispute reported 06/30/2026 1220812516
Principal investigator 1 Janssen Research & Development, LLC $3,673.00 03/10/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424832
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559565
Principal investigator 1 LivaNova USA, Inc. $918.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559568
Principal investigator 1 LivaNova USA, Inc. $969.60 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559570
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559575
Principal investigator 1 LivaNova USA, Inc. $969.60 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559577
Principal investigator 1 LivaNova USA, Inc. $918.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559581
Principal investigator 1 LivaNova USA, Inc. $969.60 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559585
Principal investigator 1 LivaNova USA, Inc. $918.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559588
Principal investigator 1 LivaNova USA, Inc. $969.60 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559592
Principal investigator 1 LivaNova USA, Inc. $969.60 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559596
Principal investigator 1 LivaNova USA, Inc. $918.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559599
Principal investigator 1 LivaNova USA, Inc. $969.60 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559604
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559609
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559613
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559617
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559620
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559626
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559628
Principal investigator 1 LivaNova USA, Inc. $72.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559632
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559636
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559643
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559648
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559660
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559665
Principal investigator 1 LivaNova USA, Inc. $282.00 03/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559670
Principal investigator 1 LivaNova USA, Inc. $700.00 03/05/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556550
Principal investigator 1 LivaNova USA, Inc. $700.00 03/05/2025 Non-covered Recipient Entity
Advarra, Inc. (Central IRB)
RECOVER: A PRospective, Multi-cEnter, Randomized Controlled Blinded Trial DemOnstrating the Safety and Effectiveness of VNS Therapy System as AdjunctivE Therapy Versus a No-Stimulation Control in Subjects With Treatment-Resistant Depression No dispute reported 06/30/2026 1245556624
Principal investigator 1 Boehringer Ingelheim International GmbH $264.55 03/04/2025 Non-covered Recipient Entity
Atp Clinical Research
A multicenter, pragmatic study to evaluate clinical effectiveness and healthcare resource utilization of a digital therapeutic (CT-155) in patients with experiential negative symptoms of schizophrenia No dispute reported 06/30/2026 1220624218
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $150.00 03/03/2025 Non-covered Recipient Entity
PNS Clinical Research LLC
A phase III trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-2) No dispute reported 06/30/2026 1220812514
Principal investigator 1 Indivior Inc. $190.25 03/03/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464778
Principal investigator 1 Indivior Inc. $190.25 03/03/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240464780
Principal investigator 1 Janssen Research & Development, LLC $13,383.00 03/03/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424808
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,500.00 02/20/2025 Non-covered Recipient Entity
Clinnova Research Solutions
An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in De Novo Subjects With DSM-5 Schizophrenia No dispute reported 06/30/2026 1235997972
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $16,947.00 02/14/2025 Non-covered Recipient Entity
Pacific Neuropsychiatric Specialists
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated with Alzheimers Disease (ADEPT-4) No dispute reported 06/30/2026 1235994806
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 02/12/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042949
Principal investigator 1 Eli Lilly and Company $15,215.00 02/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187882492
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559434
Principal investigator 1 LivaNova USA, Inc. $969.60 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559438
Principal investigator 1 LivaNova USA, Inc. $918.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559441
Principal investigator 1 LivaNova USA, Inc. $282.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559445
Principal investigator 1 LivaNova USA, Inc. $969.60 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559464
Principal investigator 1 LivaNova USA, Inc. $282.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559469
Principal investigator 1 LivaNova USA, Inc. $282.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559471
Principal investigator 1 LivaNova USA, Inc. $282.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559475
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559478
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559483
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559487
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559492
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559495
Principal investigator 1 LivaNova USA, Inc. $72.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559499
Principal investigator 1 LivaNova USA, Inc. $969.60 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559503
Principal investigator 1 LivaNova USA, Inc. $918.00 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559506
Principal investigator 1 LivaNova USA, Inc. $969.60 02/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559510
Principal investigator 1 Indivior Inc. $329.50 01/28/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A PHASE IV LONGITUDINAL STUDY OF SUBLOCADE (SUBUTEX PROLONGED RELEASE) CLINICAL OUTCOMES IN ADULTS WITH OPIOID USE DISORDER (OPIOID DEPENDENCE) No dispute reported 06/30/2026 1240463463
Principal investigator 1 Janssen Research & Development, LLC $5,432.00 01/27/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disorder (MDD) with Moderate-to-severe Anhedonia an No dispute reported 06/30/2026 1175424838
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 01/22/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042945
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $257.00 01/22/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042947
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 01/22/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042987
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 01/22/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042989
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $446.00 01/22/2025 Non-covered Recipient Entity
Clinnova Research Solutions
TV50717-CNS-40223 No dispute reported 06/30/2026 1244042991
Principal investigator 1 LivaNova USA, Inc. $72.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559448
Principal investigator 1 LivaNova USA, Inc. $969.60 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559451
Principal investigator 1 LivaNova USA, Inc. $918.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559453
Principal investigator 1 LivaNova USA, Inc. $270.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559456
Principal investigator 1 LivaNova USA, Inc. $282.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559460
Principal investigator 1 LivaNova USA, Inc. $918.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559515
Principal investigator 1 LivaNova USA, Inc. $282.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559519
Principal investigator 1 LivaNova USA, Inc. $282.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559527
Principal investigator 1 LivaNova USA, Inc. $282.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559530
Principal investigator 1 LivaNova USA, Inc. $72.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559535
Principal investigator 1 LivaNova USA, Inc. $72.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559539
Principal investigator 1 LivaNova USA, Inc. $72.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559541
Principal investigator 1 LivaNova USA, Inc. $72.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559545
Principal investigator 1 LivaNova USA, Inc. $918.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559549
Principal investigator 1 LivaNova USA, Inc. $918.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559552
Principal investigator 1 LivaNova USA, Inc. $918.00 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559556
Principal investigator 1 LivaNova USA, Inc. $969.60 01/08/2025 Non-covered Recipient Entity
PNS Clinical Research, LLC dba ATP Clinical Research
RECOVER No dispute reported 06/30/2026 1245559561
Principal investigator 1 ABBVIE INC. $33,756.52 01/03/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202436709
Principal investigator 1 ABBVIE INC. $540.00 01/03/2025 Non-covered Recipient Entity
PNS CLINICAL RESEARCH LLC
A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 (Emraclidine) in Adult Participants With Schizophrenia No dispute reported 06/30/2026 1202436717